Clinical Trial Update: Efficacy of Interleukin-2 in Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This entry notes a planned Phase 1/2 clinical trial evaluating interleukin-2 for triple-negative breast cancer, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Nova Scotia Health Authority | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING